Trial
NCT02710396
Genetic Predictors of Benefit to Pembrolizumab
Phase IITERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
Columbia University
Collaborators
Merck Sharp & Dohme LLC; Massachusetts General Hospital; National Cancer Institute (NCI)
Condition
Carcinoma, Non-Small-Cell Lung
Intervention
Pembrolizumab
Why stopped
Frontline pembrolizumab approved in NSCLC as monotherapy and in combination with chemotherapy representing a new standard of care.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2023-07-24